Search Results

Effects of omalizumab on markers of inflammation in patients with allergic asthma

Authors: Holgate, S.; Smith, N.; Massanari, M.; Jimenez, P.

Source: Allergy, Volume 64, Number 12, December 2009 , pp. 1728-1736(9)

Publisher: Blackwell Publishing

Relationship between pretreatment specific IgE and the response to omalizumab therapy

Authors: Wahn, U.; Martin, C.; Freeman, P.; Blogg, M.; Jimenez, P.

Source: Allergy, Volume 64, Number 12, December 2009 , pp. 1780-1787(8)

Publisher: Blackwell Publishing

Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma

Authors: OHTA, Ken; MIYAMOTO, Terumasa; AMAGASAKI, Taro; YAMAMOTO, Manabu

Source: Respirology, Volume 14, Number 8, November 2009 , pp. 1156-1165(10)

Publisher: Blackwell Publishing

The size of the disease relevant IgE antibody fraction in relation to `total-IgE' predicts the efficacy of anti-IgE (Xolair^®) treatment

Authors: Johansson, S. G. O.; Nopp, A.; Öman, H.; Ankerst, J.; Cardell, L. O.; Grönneberg, R.; Matsols, H.; Rudblad, S.; Strand, V.; Stålenheim, G.

Source: Allergy, Volume 64, Number 10, October 2009 , pp. 1472-1477(6)

Publisher: Blackwell Publishing

Baseline characteristics of patients enrolled in EXCELS: a cohort study

Authors: Long, Aidan A.; Fish, James E.; Rahmaoui, Abdelkader; Miller, Mary K.; Bradley, Mary S.; Taki, Hassan N.; Demeo, Anthony N.; Tilles, Stephen A.; Szefler, Stanley J.

Source: Annals of Allergy, Asthma and Immunology, Volume 103, Number 3, September 2009 , pp. 212-219(8)

Publisher: American College of Allergy, Asthma, & Immunology

The basophil activation test in the diagnosis of allergy: technical issues and critical factors

Authors: Sturm, G. J.; Kranzelbinder, B.; Sturm, E. M.; Heinemann, A.; Groselj-Strele, A.; Aberer, W.

Source: Allergy, Volume 64, Number 9, September 2009 , pp. 1319-1326(8)

Publisher: Blackwell Publishing

Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis

Authors: Kontou-Fili, K.; Filis, C. I.

Source: Allergy, Volume 64, Number 9, September 2009 , pp. 1384-1385(2)

Publisher: Blackwell Publishing

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

Authors: Lowe, Philip J.; Tannenbaum, Stacey; Gautier, Aurelie; Jimenez, Pablo

Source: British Journal of Clinical Pharmacology, Volume 68, Number 1, July 2009 , pp. 61-76(16)

Publisher: Blackwell Publishing

Off-label use of omalizumab in non-asthma conditions: new opportunities

Authors: Morjaria, Jaymin B; Polosa, Riccardo

Source: Expert Review of Respiratory Medicine, Volume 3, Number 3, June 2009 , pp. 299-308(10)

Publisher: Expert Reviews

Pathogenesis of chronic urticaria

Authors: Kaplan, A. P.; Greaves, M.

Source: Clinical & Experimental Allergy, Volume 39, Number 6, June 2009 , pp. 777-787(11)

Publisher: Blackwell Publishing

Safety and tolerability of omalizumab

Authors: Corren, J.; Casale, T. B.; Lanier, B.; Buhl, R.; Holgate, S.; Jimenez, P.

Source: Clinical & Experimental Allergy, Volume 39, Number 6, June 2009 , pp. 788-797(10)

Publisher: Blackwell Publishing

Omalizumab for asthma: pharmacology and clinical profile

Authors: Fritscher, Leandro; Chapman, Kenneth R

Source: Expert Review of Respiratory Medicine, Volume 3, Number 2, April 2009 , pp. 119-127(9)

Publisher: Expert Reviews

Comparison of the in vivo autologous skin test with in vitro diagnostic tests for diagnosis of chronic autoimmune urticaria

Authors: Altrich, Michelle L.; Halsey, John F.; Altman, Leonard C.

Source: Allergy and Asthma Proceedings, Volume 30, Number 1, January-February 2009 , pp. 28-34(7)

Publisher: OceanSide Publications, Inc

Inhibition of anti-IgE mediated human mast cell activation by NO donors is dependent on their NO release kinetics

Authors: Yip, KH; Leung, FP; Huang, Y; Lau, HYA

Source: British Journal of Pharmacology, Volume 156, Number 8, April 2009 , pp. 1279-1286(8)

Publisher: Blackwell Publishing

Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics

Author: Agoram, Balaji M.

Source: British Journal of Clinical Pharmacology, Volume 67, Number 2, February 2009 , pp. 153-160(8)

Publisher: Blackwell Publishing

Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma

Authors: Kopp, M. V.; Hamelmann, E.; Zielen, S.; Kamin, W.; Bergmann, K.-C.; Sieder, C.; Stenglein, S.; Seyfried, S.; Wahn, U.

Source: Clinical & Experimental Allergy, Volume 39, Number 2, February 2009 , pp. 271-279(9)

Publisher: Blackwell Publishing

CD200R surface expression as a marker of murine basophil activation

Authors: Torrero, M. N.; Larson, D.; Hübner, M. P.; Mitre, E.

Source: Clinical & Experimental Allergy, Volume 39, Number 3, March 2009 , pp. 361-369(9)

Publisher: Blackwell Publishing

Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment

Authors: van Rensen, E. L. J.; Evertse, C. E.; van Schadewijk, W. A. A. M.; van Wijngaarden, S.; Ayre, G.; Mauad, T.; Hiemstra, P. S.; Sterk, P. J.; Rabe, K. F.

Source: Allergy, Volume 64, Number 1, January 2009 , pp. 72-80(9)

Publisher: Blackwell Publishing

Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis

Authors: Humbert, M.; Boulet, L. P.; Niven, R. M.; Panahloo, Z.; Blogg, M; Ayre, G.

Source: Allergy, Volume 64, Number 1, January 2009 , pp. 81-84(4)

Publisher: Blackwell Publishing

Atopic and non-atopic allergic disorders: current insights into the possible involvement of free immunoglobulin light chains

Authors: Groot Kormelink, T.; Thio, M.; Blokhuis, B. R.; Nijkamp, F. P.; Redegeld, F. A.

Source: Clinical & Experimental Allergy, Volume 39, Number 1, January 2009 , pp. 33-42(10)

Publisher: Blackwell Publishing